Can AI Really Design New Drugs? Google DeepMind Spin-out Isomorphic Labs Explains
About this episode
The episode discusses the complexities of using AI in drug design with experts from Isomorphic Labs.
Can AI move from predicting proteins to actually designing new drugs? Isomorphic Labs is trying to answer one of the biggest questions in science. In this episode of The Neuron , Corey Noles and Grant Harvey talk with Rebecca Paul, Head of Medicinal Drug Design at Isomorphic Labs, and Michael Schaarschmidt, Foundational AI Research Lead. They explain why drug discovery is so slow, expensive, and failure-prone—and why AI drug design is much more complicated than “generate a molecule and ship it.” The conversation covers AlphaFold, structure prediction, molecule generation, binding models, clinical failure rates, human trust in AI systems, and the long-term hope of designing drugs for targets once considered “undruggable.” In this episode: Why drug discovery can take more than a decade What people misunderstand about “AI-designed drugs” How medicinal chemists actually use AI models Why biology is harder than text, images, or code What it would take to make drug discovery faster and cheaper The dream of designing a drug candidate in one iteration Why “undruggable” proteins may not stay undruggable forever Additional resources: Technical report blog Best resource for learning about…
More episodes of The Neuron: AI Explained
Explore listener stats, chart rankings, contacts and more on the The Neuron: AI Explained podcast page.